2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2412

Evaluating Gaps in Reproductive Health Knowledge Among Women with Rheumatic Diseases
Abstract Number: 185

Evaluating Medical Student Confidence and Performance of the Pediatric Musculoskeletal Exam
Abstract Number: 953

Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later
Abstract Number: 1382

Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Abstract Number: 199

Evaluating the Perception Among Rheumatologists of Maintenance of Board Certification Programs in the United States
Abstract Number: 1421

Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis
Abstract Number: 2198

Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
Abstract Number: 2201

Evaluation of 18f-Fluorodeoxyglucose Positron Emission Tomography/ Magnetic Resonance Imaging (18F-FDG PET/MRI) in C Protein-Induced Myositis Model in Mice
Abstract Number: 2938

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
Abstract Number: 1716

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Abstract Number: 1993

Evaluation of Cartilage Degeneration and Osteoarthritis Pain on Female and Male Mouse Model of Osteoarthritis
Abstract Number: 2812

Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Abstract Number: 570

Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
Abstract Number: 1677

Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 792

Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].